Foundational Peptides
Core research and establishing principles in peptide therapy.
Start Here: The Language of Cells Primer
Your cells are constantly talking to one another. Before exploring specific compounds, start with Dr. Woods' foundational masterclass: Speaking the Language of Cells. This 14-page visual guide explains how to move from passively treating symptoms to becoming the architect of your own biology. Learn the core mechanisms, delivery methods, and the science behind aging, repair, and vitality.
Beginner Research Pathway
Click to reveal detailed, beginner-friendly instructions.
In Plain English: Peptides are short chains of amino acids that act as your body's native signaling language. Because our natural production of these vital messengers drops as we age, targeted peptide therapy is becoming a cornerstone of proactive health. By binding to specific cellular receptors, they trigger precise actions like reducing inflammation, stimulating healing, or balancing the immune system. In fact, popular medications like Ozempic demonstrate just how powerful and mainstream peptide therapies have become.
Peptides are the body's native signaling language. These short chains of amino acids bind to specific cellular receptors to trigger precise biological actions - from reducing inflammation and stimulating growth hormone release to modulating the immune system. Because our natural endogenous peptide production declines significantly as we age, targeted exogenous peptide therapy is becoming a cornerstone of proactive health. In fact, some of the most widely recognized and FDA-approved medications on the market today - such as the GLP-1 agonist Ozempic (semaglutide) - are peptide therapies, demonstrating the profound clinical power of these compounds.
2026 Regulatory Deep Dive
2026 Status Report: While Secretary RFK Jr. stated on Feb 27, 2026, that the FDA is considering moving ~14 peptides back to Category 1 status 'within weeks,' no official HHS press release has been finalized.
Key Impacted Peptides: BPC-157, TB-500, Thymosin Alpha-1, CJC-1295, Ipamorelin, AOD-9604, Selank, Semax, MOTS-C, KPV, and GHK-Cu.
Important Nuance: Even if reclassified, these remain non-FDA-approved compounds requiring a physician's prescription and preparation by licensed 503A compounding pharmacies.
US & Canada Peptide Regulatory Status
Last Updated: March 2026
| Peptide | US (FDA) Status | Canada (Health Canada) Status |
|---|---|---|
| AOD-9604 | Category 1 (March 2026 - Restored for Compounding) | Health Canada Agile Licensing Review (March 2026) |
| BPC-157 | Category 1 (March 2026 - Restored for Compounding) | Health Canada Agile Licensing Review (March 2026) |
| CJC-1295 | Category 1 (March 2026 - Restored for Compounding) | Health Canada Agile Licensing Review (March 2026) |
| Epitalon | Category 1 (March 2026 - Restored for Compounding) | Health Canada Agile Licensing Review (March 2026) |
| GHK-Cu (Injectable) | Category 1 (March 2026 - Restored for Compounding) | Health Canada Agile Licensing Review (March 2026) |
| Ipamorelin | Category 1 (March 2026 - Restored for Compounding) | Health Canada Agile Licensing Review (March 2026) |
| Kisspeptin-10 | Category 1 (March 2026 - Restored for Compounding) | Health Canada Agile Licensing Review (March 2026) |
| KPV | Category 1 (March 2026 - Restored for Compounding) | Health Canada Agile Licensing Review (March 2026) |
| Melanotan II | Category 2 - Restricted | Health Canada Agile Licensing Review (March 2026) |
| MOTS-C | Category 1 (March 2026 - Restored for Compounding) | Health Canada Agile Licensing Review (March 2026) |
| Selank | Category 1 (March 2026 - Restored for Compounding) | Health Canada Agile Licensing Review (March 2026) |
| Semax | Category 1 (March 2026 - Restored for Compounding) | Health Canada Agile Licensing Review (March 2026) |
| Thymosin Alpha-1 | Category 1 (March 2026 - Restored for Compounding) | Health Canada Agile Licensing Review (March 2026) |
| Thymosin Beta-4 (TB-500) | Category 1 (March 2026 - Restored for Compounding) | Health Canada Agile Licensing Review (March 2026) |
Quick-Start Targeting Matrix: Most Commonly Researched Peptides
Categorized by primary research goal
| Primary Goal | Common Peptides |
|---|---|
| Healing & Recovery | BPC-157 TB-500 |
| Fat Loss & Metabolism | AOD-9604 MOTS-C |
| Growth Hormone Secretagogues | CJC-1295 Ipamorelin |
| Immunity & Inflammation | Thymosin Alpha-1 KPV |
| Longevity & Anti-Aging | Epitalon GHK-Cu |
| Cognitive & Nootropic | Selank Semax |
| Libido & Pigmentation | Melanotan II |
| Hormonal Balance | Kisspeptin-10 |
For Educational & Research Purposes Only. Not Medical Advice.
Live Research Search
Note: The Europe PMC database pulls directly from US PubMed, MEDLINE, and international grants.
| Research Paper Title | Focus Area | Year | Key Takeaway | Action |
|---|---|---|---|---|
|
Therapeutic
Peptides: Current Applications
Wang et al.
|
General applications and advancements in improving Bioavailability. | 2022 | Reviews how chemical modifications have overcome classical shortcomings, leading to expanded Subcutaneous and oral options. | View Full Text |
|
Trends in
Peptide Drug Discovery
Muttenthaler et al.
|
New molecular design trends shaping the next decade. | 2021 | Highlights the resurgence in peptide drug discovery powered by new formulation strategies. | View Full Text |